Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Patients, physicians, and hospital administrators in the USA are often unaware of how legislation governs medical data—but agree that rights over such data should be expanded for patients and curtailed for health systems
Findings from the SURPASS-AP-Combo trial demonstrate that addition of tirzepatide is non-inferior and superior to insulin glargine for glycemic outcomes at 40 weeks when used as second-line or third-line therapy in an Asia-Pacific (predominantly Chinese) population with type 2 diabetes.
In an open-label, randomized controlled trial, normothermic machine perfusion of kidneys from donation after circulatory death was found to be feasible and safe but did not reduce the rate of delayed graft function compared to static cold storage.
For women who choose nonhormonal therapy for hot flashes, fezolinetant appears to be one of several modestly efficacious and safe options — but women want more.
Nature Medicine explores the latest translational and clinical research news, with FDA approval of Seres’ orally administered pill SER-109 for the treatment of recurrent Clostridioidesdifficile infection.
A large, publicly available dataset integrating RNA, whole-exome, T cell receptor and 16S rRNA sequencing from patients with colon cancer enables the discovery of a prognostic score consisting of tumor, immune and microbial features.
The health sector must play its part in decarbonization efforts; this Perspective outlines the principles of fair pathways to net-zero healthcare that are attentive to health and socioeconomic inequalities.
Multilevel stakeholder engagement in policy decision-making and implementation-planning is needed to build trust and deliver evidence-based health interventions.
We characterized cancer cells, immune responses and the microbiota composition in a cohort of primary colon cancers. Multi-omic analyses defined parameters associated with favorable prognosis, including a score that captured the intratumoral immune response and a specific microbiome signature. This data repository (atlas and compass of immune–cancer–microbiome interactions (AC-ICAM)) is publicly available.
An antisense oligonucleotide therapy substantially reduced tau expression in a phase 1b trial; whether this translates to clinical improvement remains to be seen, but it could have far-reaching implications for neurodegenerative diseases more broadly.
Machine learning models that integrate cardiac troponin concentrations and clinical features to compute the probability of myocardial infarction outperform current care pathways that use fixed troponin thresholds or risk scores. Adoption of these models could reduce inequalities, prevent unnecessary admissions, and accelerate the diagnosis and treatment of patients with myocardial infarction.
Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
Adding an oncolytic virus to classic immune checkpoint inhibition elicits treatment responses and survival benefit for select immunologically ‘cold’ recurrent glioblastomas, although creative treatment strategies are still needed for patients with highly anti-inflammatory tumors.